Eric Furfine,Daniel Dix,Kenneth S. Graham,Kelly Frye
申请号：
US12833417
公开号：
US08092803B2
申请日:
2010.07.09
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.
